449 related articles for article (PubMed ID: 32210965)
1. Advances in Developing CAR T-Cell Therapy for HIV Cure.
Qi J; Ding C; Jiang X; Gao Y
Front Immunol; 2020; 11():361. PubMed ID: 32210965
[TBL] [Abstract][Full Text] [Related]
2. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
3. Development of CAR-T cells for long-term eradication and surveillance of HIV-1 reservoir.
Liu B; Zhang W; Zhang H
Curr Opin Virol; 2019 Oct; 38():21-30. PubMed ID: 31132749
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
Yang H; Wallace Z; Dorrell L
Front Immunol; 2018; 9():2861. PubMed ID: 30564246
[TBL] [Abstract][Full Text] [Related]
6. HIV-Resistant and HIV-Specific CAR-Modified CD4
Maldini CR; Gayout K; Leibman RS; Dopkin DL; Mills JP; Shan X; Glover JA; Riley JL
Mol Ther; 2020 Jul; 28(7):1585-1599. PubMed ID: 32454027
[TBL] [Abstract][Full Text] [Related]
7. Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology.
Mylvaganam G; Yanez AG; Maus M; Walker BD
Front Immunol; 2019; 10():2109. PubMed ID: 31552045
[TBL] [Abstract][Full Text] [Related]
8. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
9. Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir
York J; Gowrishankar K; Micklethwaite K; Palmer S; Cunningham AL; Nasr N
Front Immunol; 2022; 13():873701. PubMed ID: 35572509
[TBL] [Abstract][Full Text] [Related]
10. Current status and future development of anti-HIV chimeric antigen receptor T-cell therapy.
Mao Y; Zhao C; Zheng P; Zhang X; Xu J
Immunotherapy; 2021 Feb; 13(2):177-184. PubMed ID: 33225803
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor T-cell approaches to HIV cure.
Kuhlmann AS; Peterson CW; Kiem HP
Curr Opin HIV AIDS; 2018 Sep; 13(5):446-453. PubMed ID: 29878913
[TBL] [Abstract][Full Text] [Related]
12. T-cell therapies for HIV: Preclinical successes and current clinical strategies.
Patel S; Jones RB; Nixon DF; Bollard CM
Cytotherapy; 2016 Aug; 18(8):931-942. PubMed ID: 27265874
[TBL] [Abstract][Full Text] [Related]
13. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
14. Fight fire with fire: Gene therapy strategies to cure HIV.
Huyghe J; Magdalena S; Vandekerckhove L
Expert Rev Anti Infect Ther; 2017 Aug; 15(8):747-758. PubMed ID: 28692305
[TBL] [Abstract][Full Text] [Related]
15. Simian Immunodeficiency Virus (SIV)-Specific Chimeric Antigen Receptor-T Cells Engineered to Target B Cell Follicles and Suppress SIV Replication.
Haran KP; Hajduczki A; Pampusch MS; Mwakalundwa G; Vargas-Inchaustegui DA; Rakasz EG; Connick E; Berger EA; Skinner PJ
Front Immunol; 2018; 9():492. PubMed ID: 29616024
[TBL] [Abstract][Full Text] [Related]
16. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies.
Chun TW; Justement JS; Moir S; Hallahan CW; Ehler LA; Liu S; McLaughlin M; Dybul M; Mican JM; Fauci AS
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):253-8. PubMed ID: 11136258
[TBL] [Abstract][Full Text] [Related]
17. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.
Anthony-Gonda K; Bardhi A; Ray A; Flerin N; Li M; Chen W; Ochsenbauer C; Kappes JC; Krueger W; Worden A; Schneider D; Zhu Z; Orentas R; Dimitrov DS; Goldstein H; Dropulić B
Sci Transl Med; 2019 Aug; 11(504):. PubMed ID: 31391322
[TBL] [Abstract][Full Text] [Related]
18. Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1.
Liu B; Zhang W; Xia B; Jing S; Du Y; Zou F; Li R; Lu L; Chen S; Li Y; Hu Q; Lin Y; Zhang Y; He Z; Zhang X; Chen X; Peng T; Tang X; Cai W; Pan T; Li L; Zhang H
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34375315
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS.
Zhen A; Peterson CW; Carrillo MA; Reddy SS; Youn CS; Lam BB; Chang NY; Martin HA; Rick JW; Kim J; Neel NC; Rezek VK; Kamata M; Chen ISY; Zack JA; Kiem HP; Kitchen SG
PLoS Pathog; 2017 Dec; 13(12):e1006753. PubMed ID: 29284044
[TBL] [Abstract][Full Text] [Related]
20. Generation of Anti-HIV CAR-T Cells for Preclinical Research.
Su H; Anthony-Gonda K; Orentas RJ; Dropulić B; Goldstein H
Methods Mol Biol; 2024; 2807():287-298. PubMed ID: 38743236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
